<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27927" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Pseudocholinesterase</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Benner</surname>
            <given-names>Andrew</given-names>
          </name>
          <aff>Michigan State University - College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lewallen</surname>
            <given-names>Noble F.</given-names>
          </name>
          <aff>Michigan State University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sadiq</surname>
            <given-names>Nazia M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Benner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noble Lewallen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nazia Sadiq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27927.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pseudocholinesterase is a serine hydrolase enzyme primarily produced in the liver that catalyzes the hydrolysis of choline esters, most prominently succinylcholine and mivacurium.<xref ref-type="bibr" rid="article-27927.r1">[1]</xref> It is crucial to differentiate this enzyme from "true" cholinesterase, also known as acetylcholinesterase. It occurs in higher concentrations within conducting tissues such as the central&#x000a0;or peripheral nervous systems and neuromuscular junctions.<xref ref-type="bibr" rid="article-27927.r2">[2]</xref> Due to diverse functions and tissue distribution within the human body, pseudocholinesterase often gets referred to through various enzymatic names, including plasma cholinesterase, serum cholinesterase, acetylcholine acetylhydrolase, and butyrylcholinesterase (BuChE).<xref ref-type="bibr" rid="article-27927.r3">[3]</xref></p>
        <p>In addition to possessing multiple names, the enzyme exists in many pharmacogenetic variations, with BuChE operating as the primary human cholinesterase form. When comparing concentrations within the human plasma, the ratio of pseudocholinesterase (BuChE) to true cholinesterase (AChE) overwhelmingly favors BuChE by a ratio of 1000 to 1.<xref ref-type="bibr" rid="article-27927.r3">[3]</xref></p>
      </sec>
      <sec id="article-27927.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>BuChE functions primarily as a serine hydrolase that catalyzes the hydrolysis of choline and noncholine esters and maintains active aryl acrylamide, amplifying the action of trypsin and other proteases within the body.<xref ref-type="bibr" rid="article-27927.r4">[4]</xref> BuChE predominately influences the activity of&#x000a0;neurons, specifically within the hippocampus, amygdala, thalamus, and different deep layers of the cerebral cortex.<xref ref-type="bibr" rid="article-27927.r4">[4]</xref> BuChE appears to serve a functional role in the maturation of the central and peripheral nervous systems through regulating neuronal growth and cellular proliferation, especially at the onset of differentiation and throughout the early stages of neuronal development.<xref ref-type="bibr" rid="article-27927.r5">[5]</xref></p>
      </sec>
      <sec id="article-27927.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Pseudocholinesterase (butyrylcholine esterase) deficiency causes increased sensitivity to choline ester muscle relaxant medications: succinylcholine and mivacurium. In correlation to the level/variant of BuChE deficiency, patients exposed to these neuromuscular blockade agents may experience an amplified duration of apnea and paralysis ranging from mild to extreme.<xref ref-type="bibr" rid="article-27927.r6">[6]</xref> In the presence of BuChE deficiency, the usual course of action for succinylcholine-induced paralysis gets prolonged from approximately 4 to 6 minutes to up to 8 hours. These patients may also exhibit significant sensitivity to agricultural pesticides (organophosphates), cocaine, and ester local anesthetics, such as procaine.<xref ref-type="bibr" rid="article-27927.r6">[6]</xref></p>
        <p>Should persistent respiratory depression occur,&#x000a0;most commonly due to succinylcholine administration in the presence of BuChE deficiency, the mainstay of therapy focuses on prolonged ventilatory support. Positive pressure ventilation is required until skeletal muscle regains adequate neuromuscular function following passive diffusion of succinylcholine from the neuromuscular&#x000a0;junction.<xref ref-type="bibr" rid="article-27927.r7">[7]</xref> Patients with known BuChE deficiency status should disclose this information to all medical personnel through a medical alert band, notifying clinicians of increased sensitivity to mivacurium and succinylcholine in case an emergency arises.&#x000a0;</p>
      </sec>
      <sec id="article-27927.s4" sec-type="Molecular Level&#x0000d;&#x0000a;">
        <title>Molecular Level
</title>
        <p>The coding gene for BuChE coincides with multiple polymorphisms, resulting in wide variability in the level of activity of each variant, including silent variants with little to no enzymatic function.<xref ref-type="bibr" rid="article-27927.r4">[4]</xref> Depending on the type and location of the gene mutation, alterations in enzyme structure/function or cessation of enzyme synthesis may occur. Specifically, point mutations alter the enzyme's structure due to changes in the mRNA and amino acids compiled during enzyme production, often resulting in abnormal function. Meanwhile, mutations that result in a stop codon or frameshift often lead to dysfunctional enzyme synthesis. Within each molecular form of pseudocholinesterase, there are several sub-variants, defined by the number and orientation of subunits within the molecule; ranging from single monomers (G1) to&#x000a0;2 symmetric monomers (dimer, G2) to dimers conjoined by disulfide bridges (tetramer, G4).<xref ref-type="bibr" rid="article-27927.r8">[8]</xref></p>
      </sec>
      <sec id="article-27927.s5" sec-type="Testing">
        <title>Testing</title>
        <p>The diagnosis of pseudocholinesterase deficiency most commonly occurs through family history and clinical context of prolonged apnea and paralysis following depolarizing neuromuscular blockade via succinylcholine. With an autosomal recessive inheritance pattern and a heterozygous gene frequency ranging from 1 in 25 to 1 in 50, family members of known homozygotes must undergo testing for the presence of an altered BCHE gene.<xref ref-type="bibr" rid="article-27927.r9">[9]</xref> Confirmation of BuChE deficiency may occur through gene sequencing of the coding gene, <italic toggle="yes">BCHE</italic>, located at 3q26.1, via techniques such as deletion&#x000a0;or duplication analysis, targeted variant analysis, or sequence analysis of the entire gene coding region.</p>
      </sec>
      <sec id="article-27927.s6" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The onset of pseudocholinesterase deficiency may occur through inheritable (genetic) or acquired pathways.&#x000a0;Despite its etiology, pseudocholinesterase deficiency usually does not have clinically significant effects until the enzyme activity decreases to less than 75% of normal activity levels.<xref ref-type="bibr" rid="article-27927.r10">[10]</xref></p>
        <p>The genetic inheritance of pseudocholinesterase deficiency occurs through an autosomal recessive pattern, with frequencies of approximately 1 in 50 to 1 in 3000 individuals for heterozygotes and homozygotes, respectively.<xref ref-type="bibr" rid="article-27927.r9">[9]</xref> The prevalence of BuChE deficiency is highest amongst those with European ancestry and lowest within the Asian population.</p>
        <p>Acquired conditions that decrease the activity of the BuChE enzyme include malnutrition, advanced age, malignancy, liver&#x000a0;or kidney disease, pregnancy, burns, and organophosphate poisoning. In contrast, obesity and chronic alcoholism are suspected to increase pseudocholinesterase activity levels. Medications such as aspirin, metoclopramide, monoamine oxidase inhibitors, oral contraceptives, and anticholinesterase agents may also influence the enzyme's activity.<xref ref-type="bibr" rid="article-27927.r9">[9]</xref> Through hydrolysis and sequestration of toxic compounds, the broad substrate specificity of BuChE&#x000a0;may protect against numerous inhaled and administered&#x000a0;substances.<xref ref-type="bibr" rid="article-27927.r11">[11]</xref></p>
      </sec>
      <sec id="article-27927.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>There is conflicting evidence as to whether pseudocholinesterase deficiency plays a role in the progression of Alzheimer's disease. However, increased levels of BuChE and altered structure&#x000a0;or function of the enzyme are observable in patients with Alzheimer disease, specifically within the pathognomonic amyloid plaques and neurofibrillary tangles.<xref ref-type="bibr" rid="article-27927.r4">[4]</xref> Furthermore, BuChE may exhibit a synergistic role with ApoE4 in causing mild cognitive impairment.<xref ref-type="bibr" rid="article-27927.r12">[12]</xref></p>
        <p>Plasma cholinesterase levels were significantly higher in patients with drug addictions (most notably, cocaine) than those without, suggesting it serves a significant role in addiction pathophysiology.<xref ref-type="bibr" rid="article-27927.r13">[13]</xref> BuChE gene amplification and elevated enzyme activities are also prevalent in tumorigenesis and neuronal disorders, potentially allowing researchers to target gene expression as a unique treatment modality.<xref ref-type="bibr" rid="article-27927.r5">[5]</xref></p>
        <p>Hepatocytes function as the primary synthesis pathway for plasma cholinesterase. Serum levels of plasma cholinesterase may serve as a valuable biomarker of liver function with an excellent correlation to the currently accepted standards of serum albumin, prothrombin time/international normalized ratio, and MELD score (Model for End-Stage Liver Disease).<xref ref-type="bibr" rid="article-27927.r14">[14]</xref> Levels of serum cholinesterase may also serve as a prognostic marker for advanced liver disease secondary to distinguishing between decompensated and compensated cirrhosis, reflected by low and high enzyme levels, respectively.<xref ref-type="bibr" rid="article-27927.r14">[14]</xref> In addition to its association with liver function, BuChE may also correlate significantly with the role of red blood cells and kidneys.<xref ref-type="bibr" rid="article-27927.r3">[3]</xref><xref ref-type="bibr" rid="article-27927.r15">[15]</xref></p>
      </sec>
      <sec id="article-27927.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27927&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27927">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27927/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27927">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27927.s9">
        <title>References</title>
        <ref id="article-27927.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Goudsouzian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Martyn</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Pseudocholinesterase-mediated hydrolysis is superior to neostigmine for reversal of mivacurium-induced paralysis in vitro.</article-title>
            <source>Anesthesiology</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>84</volume>
            <issue>4</issue>
            <fpage>936</fpage>
            <page-range>936-44</page-range>
            <pub-id pub-id-type="pmid">8638849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colovi&#x00107;</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Krsti&#x00107;</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Lazarevi&#x00107;-Pa&#x00161;ti</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Bond&#x0017e;i&#x00107;</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vasi&#x00107;</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholinesterase inhibitors: pharmacology and toxicology.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2013</year>
            <month>May</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-35</page-range>
            <pub-id pub-id-type="pmid">24179466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tunsaringkarn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zapuang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rungsiyothin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Correlative Study of Serum Pseudo-cholinesterase, Biological Parameters and Symptoms Among Occupational Workers.</article-title>
            <source>Indian J Clin Biochem</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>396</fpage>
            <page-range>396-402</page-range>
            <pub-id pub-id-type="pmid">24426243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darvesh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Geula</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Neurobiology of butyrylcholinesterase.</article-title>
            <source>Nat Rev Neurosci</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-8</page-range>
            <pub-id pub-id-type="pmid">12563284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robitzki</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5'butyrylcholinesterase-DNA study.</article-title>
            <source>Prog Neurobiol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>607</fpage>
            <page-range>607-28</page-range>
            <pub-id pub-id-type="pmid">10739090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuhnert</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Philipson</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Pimental</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kuhnert</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>A prolonged chloroprocaine epidural block in a postpartum patient with abnormal pseudocholinesterase.</article-title>
            <source>Anesthesiology</source>
            <year>1982</year>
            <month>Jun</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>477</fpage>
            <page-range>477-8</page-range>
            <pub-id pub-id-type="pmid">7081736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosenquist</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arias</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McCall</surname>
                <given-names>WV</given-names>
              </name>
            </person-group>
            <article-title>Pseudocholinesterase deficiency and electroconvulsive therapy.</article-title>
            <source>J ECT</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>198</fpage>
            <page-range>198-200</page-range>
            <pub-id pub-id-type="pmid">17805000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atack</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Bonham</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Candy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system.</article-title>
            <source>J Neurochem</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>263</fpage>
            <page-range>263-77</page-range>
            <pub-id pub-id-type="pmid">3711902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Butyrylcholinesterase deficiency identified by preoperative patient interview.</article-title>
            <source>Korean J Anesthesiol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>6 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-3</page-range>
            <pub-id pub-id-type="pmid">24478828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soliday</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Conley</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Henker</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences.</article-title>
            <source>AANA J</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>313</fpage>
            <page-range>313-20</page-range>
            <pub-id pub-id-type="pmid">20879632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jasiecki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x0017b;uk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krawczy&#x00144;ska</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jo&#x00144;ca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szczoczarz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewandowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Waleron</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Was&#x00105;g</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Haplotypes of butyrylcholinesterase K-variant and their influence on the enzyme activity.</article-title>
            <source>Chem Biol Interact</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>307</volume>
            <fpage>154</fpage>
            <page-range>154-157</page-range>
            <pub-id pub-id-type="pmid">31071335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabriel</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Carneiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Val&#x000e9;rio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pinheiro</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Pascoal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Santana</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baldeiras</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2018</year>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>1097</fpage>
            <page-range>1097-1105</page-range>
            <pub-id pub-id-type="pmid">29254094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Awan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bibi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tanveer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Batool</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nurulain</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder.</article-title>
            <source>J Mol Neurosci</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>445</fpage>
            <page-range>445-455</page-range>
            <pub-id pub-id-type="pmid">30707402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramachandran</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sajith</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Priya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Balasubramanian</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Serum cholinesterase is an excellent biomarker of liver cirrhosis.</article-title>
            <source>Trop Gastroenterol</source>
            <year>2014</year>
            <season>Jan-Mar</season>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-20</page-range>
            <pub-id pub-id-type="pmid">25276901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27927.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zarday</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Deery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tellis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Soberman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foldes</surname>
                <given-names>FF</given-names>
              </name>
            </person-group>
            <article-title>Plasma and red cell cholinesterase activity in uremic patterns (effects of hemodialysis and renal transplantation).</article-title>
            <source>J Med</source>
            <year>1975</year>
            <volume>6</volume>
            <issue>5-6</issue>
            <fpage>337</fpage>
            <page-range>337-49</page-range>
            <pub-id pub-id-type="pmid">768397</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
